Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies
Oncology Reports, 2006 The p16 protein is a cyclin-dependent kinase (CDK) inhibitor, which plays an important role in the regulation of the cell cycle by inactivating the cyclin-dependent kinase (CDK) that phosphorylates the retinoblastoma (Rb) protein. Overexpression of p16 protein has been found in many types of human malignancy.
Looi, Koksun +5 more
openaire +3 more sources
p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1.
PLoS ONE, 2011 BackgroundThe cyclin-D/CDK4,6/p16(INK4a)/pRB/E2F pathway, a key regulator of the critical G1 to S phase transition of the cell cycle, is universally disrupted in human cancer.
Huda H Al-Khalaf +8 more
doaj +1 more source
The light and shadow of senescence and inflammation in cardiovascular pathology and regenerative medicine [PDF]
, 2017 Recent epidemiologic studies evidence a dramatic increase of cardiovascular diseases, especially associated with the aging of the world population. During aging, the progressive impairment of the cardiovascular functions results from the compromised ...
Cavarretta, Elena +9 more
core +4 more sources
eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]
, 2019 CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina +13 more
core +1 more source
Neoplasia: An International Journal for Oncology Research, 1999 After in-vitro exposure to 0.05 μmol/L 9-nitrocamptothecin (9NC) for periods of time longer than 5 days, 65% to 80% of the human malignant melanoma SB1 B cells die by apoptosis, whereas the remaining cells are arrested at the G2-phase of the cell cycle ...
Panayotis Pantazis +3 more
doaj +1 more source
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. [PDF]
PLoS ONE, 2014 Epigenetic silencing of tumour suppressor genes has been observed in various cancers. Looking at hepatocellular carcinoma (HCC) specific protein silencing was previously demonstrated to be associated with the Hepatitis C virus (HCV).
Inga Hinrichsen +6 more
doaj +1 more source
Histopathological characteristics and coexpression of p53 and p16INK4a proteins in renal cancer [PDF]
Vojnosanitetski Pregled, 2008 Background/Aim. Renal carcinoma represents histologically heterogeneous group of malignant tumors, with various clinical aggressiveness. The frequency of p53 mutation in primal renal carcinoma is rare, although there are information about its ...
Živković Slađana +3 more
doaj +1 more source
BMJ Open, 2019 Introduction Over the past decades, the number of people with type 2 diabetes (T2D) has increased globally. One of the major complications in these patients is cardiovascular disease; it seems that the cell proliferation inhibition can improve vascular ...
Shima Abdollahi +8 more
doaj +1 more source
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
Biomolecules, 2020 Genetic alterations in the INK4a/ARF (or CDKN2A) locus have been reported in many cancer types, including melanoma; head and neck squamous cell carcinomas; lung, breast, and pancreatic cancers.
Zizhen Ming, Su Yin Lim, Helen Rizos
doaj +1 more source
The ING1a tumor suppressor regulates endocytosis to induce cellular senescence via the Rb-E2F pathway. [PDF]
PLoS Biology, 2013 The INhibitor of Growth (ING) proteins act as type II tumor suppressors and epigenetic regulators, being stoichiometric members of histone acetyltransferase and histone deacetylase complexes. Expression of the alternatively spliced ING1a tumor suppressor
Uma Karthika Rajarajacholan +2 more
doaj +1 more source